WATCH LIVE
timothy sykes logo
ABCL Jumps As Jazz Deal Fuels Antibody Pipeline Momentum Thumbnail
G Google News

ABCL Jumps As Jazz Deal Fuels Antibody Pipeline Momentum

TIM SYKES•UPDATED JUN. 29, 2026, 11:33 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

AbCellera Biologics Inc. stocks have been trading up by 8.74 percent amid heightened optimism over its antibody discovery platform.

Key Takeaways

  • AbCellera entered a preclinical collaboration, option, and license agreement with Jazz Pharmaceuticals to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, receiving $56 million upfront plus $28 million tied to a third program and eligibility for up to $792 million per program in milestones and tiered royalties.
  • Under the Jazz deal, AbCellera will run discovery and early-stage work on at least three T-cell engaging multispecific antibody programs in exchange for a total of $84 million in upfront payments and potential milestones of up to $792 million per program plus royalties on future sales.
  • AbCellera shares rose roughly 2% to 4% in premarket trading after announcing the Jazz Pharmaceuticals collaboration focused on T-cell engaging multispecific antibodies.
  • AbCellera appointed Dr. Victor Sandor, former Chief Medical Officer at Array BioPharma with a track record of multiple approved cancer therapies, as an independent member of its Board of Directors.

Candlestick Chart

Live Update At 11:32:28 EDT: On Monday, June 29, 2026 AbCellera Biologics Inc. stock [NASDAQ: ABCL] is trending up by 8.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ABCL has turned into a momentum story on the chart, even while the fundamentals still show a young, cash-burning biotech platform. Over the past few weeks, AbCellera Biologics Inc. has run from a close of $5.24 on 2026/06/12 to $8.04 on 2026/06/29. That’s a sharp trend higher, with the last three sessions alone stepping from $6.03 to $7.38 to $8.04. For short-term traders, that’s a clean series of higher highs and higher lows.

Intraday on 2026/06/29, ABCL held the move. After gapping from a premarket base around $7.70–$7.80, the stock pushed to an $8.42 high and then consolidated in a tight band near $8.20 before easing to close near $8.04. That intraday action shows buyers supporting dips instead of bailing at the first sign of weakness.

On the fundamentals, ABCL is still deeply unprofitable. Latest quarterly numbers show revenue of only about $8.3M against operating expenses of roughly $65.8M, leading to an operating loss of around $57.5M and a net loss near $43.2M. Profit margins are sharply negative, with EBIT margin more than -200%.

More Breaking News

But AbCellera Biologics Inc. carries a strong balance sheet: roughly $504.7M in cash and short-term investments, very low debt, and a current ratio above 14. That liquidity gives ABCL runway to execute partnerships like the new Jazz deal without leaning on dilutive capital raises in the near term.

Why Traders Are Watching ABCL After The Jazz Deal

Traders are crowding into ABCL because the Jazz Pharmaceuticals collaboration finally puts hard numbers behind the antibody discovery story. AbCellera Biologics Inc. is getting $56M upfront, plus $28M tied to a third program, for discovery and early research on at least three T‑cell engaging multispecific antibody programs. Total upfront economics stand at $84M, which is a big non-dilutive boost relative to ABCL’s recent quarterly revenue base.

The real lure, though, is the back-end. For each program, ABCL is eligible for up to $792M in milestones, plus tiered royalties on future sales if Jazz exercises its options and pushes the drugs forward. For a platform company like AbCellera Biologics Inc., that means multiple shots on goal in GI cancers and other solid tumors, with a large-cap partner taking on the heavy lift of late-stage trials and commercialization.

The market’s response has been clear. Headlines show ABCL shares jumping roughly 2%–4% in premarket trading on the news, and the multi-day chart backs that up with a strong breakout from the mid-$5s to above $8. Traders love that combination: fresh catalyst, strong volume, and a structure where ABCL gets paid early while keeping upside tied to milestones and royalties.

This deal also lines up with the boardroom move ABCL made earlier in the month. AbCellera Biologics Inc. added Dr. Victor Sandor, former CMO at Array BioPharma, as an independent director. His track record with multiple approved cancer therapies fits directly with ABCL’s growing oncology push and should help guide how the company selects and advances partnered programs. For active traders, that added clinical brainpower can be another confidence signal that AbCellera Biologics Inc. is serious about turning its discovery engine into real, approvable drugs.

Conclusion

For traders studying ABCL, the setup is straightforward: a small-cap biotech platform with heavy losses but a strong cash position, now validated by a sizable collaboration with Jazz. AbCellera Biologics Inc. just proved that big pharma is willing to write meaningful checks for its antibody discovery capabilities. Those $84M in upfront payments, layered with up to $792M per program in milestones and royalties, give ABCL leverage if even one of these T‑cell engaging multispecific antibody programs hits.

At the same time, the charts confirm rising interest. ABCL has broken out from a long base in the mid-$5s and is now trending with expanding ranges and tight intraday consolidations near the highs. That’s classic momentum behavior that short-term traders in the Tim Sykes universe watch closely. As Tim Sykes loves to remind his community, “react, don’t predict” — let the price action and volume confirm that a story like AbCellera Biologics Inc. is truly in play before risking capital. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”.

The board addition of Dr. Victor Sandor ties the narrative together. AbCellera Biologics Inc. now pairs deeper oncology expertise with a rich, multi-program partnership focused on solid tumors. For education-focused traders, the key is to treat ABCL as a case study: strong catalyst, clear technical trend, and well-defined risk, not a guarantee of future gains. This article is for educational and research purposes only and does not represent investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”